Fosun Pharma Commences Phase I Clinical Trial for Nuclear Medicine Project SRT-007
December 31, 2025
Source: drugdu
61
Beijing Business Today News (December 30): Fosun Pharma announced that its subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has initiated Phase I clinical trials in Mainland China (excluding Hong Kong, Macau, and Taiwan) for SRT-007, an integrated diagnostic and therapeutic (theranostic) nuclear medicine project. The indication is for the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
According to the announcement, the theranostic project SRT-007 consists of two injections: Gallium [68Ga] PSMA-0057 (for diagnosis) and Lutetium [177Lu] PSMA-0057 (for treatment). Specifically, Gallium [68Ga] PSMA-0057 injection is a diagnostic radiopharmaceutical, while Lutetium [177Lu] PSMA-0057 injection is a therapeutic radiopharmaceutical.
https://finance.eastmoney.com/a/202512303605807463.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Betamethasone Sodium Phosphate Injection Approved January 9, 2026
- OpenAI releases two AI products in the healthcare field. January 9, 2026
- Say goodbye to lifelong medication? Hepatitis B patients may be entering an era of “functional cure”. January 9, 2026
- Xuantai Pharmaceutical’s “Isaconazole Sulfate for Injection” has been approved for marketing by the National Medical Products Administration, enriching new options for antifungal treatment January 9, 2026
- Fosun Pharma resubmits its application for listing of Furuitinib January 9, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
